8-K: Elicio Therapeutics Updates Q3 2025, Extends Cash Runway

Elicio Therapeutics reports Q3 2025 financial results, provides corporate updates, and extends its cash runway through Q2 2026, with Phase 2 AMPLIFY-7P data now expected in 1H 2026.

Summary

• Fewer disease progressions and deaths than projected have been observed in the Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (PDAC) as of November 6, 2025.
• This observation may reflect a favorable impact on disease-free survival (DFS), leading to an event-driven primary DFS analysis now anticipated in 1H 2026.
• The company has raised approximately $11.1 million in gross proceeds through its at-the-market program since the beginning of Q3 2025.
• Current cash and cash equivalents of $20.6 million as of September 30, 2025, are expected to support operations through Q2 2026, beyond the anticipated Phase 2 AMPLIFY-7P event-driven primary DFS endpoint analysis.
• Research and development (R&D) expense for Q3 2025 was $5.0 million, a decrease from $7.2 million in Q3 2024.
• General and administrative (G&A) expense for Q3 2025 was $3.0 million, a decrease from $3.1 million in Q3 2024.
• Net loss for Q3 2025 significantly improved to $10.1 million, compared to $18.8 million for Q3 2024.
• Net loss per share for Q3 2025 was $0.60, an improvement from $1.39 for Q3 2024.
• Updated Phase 2 AMPLIFY-7P data presented in November 2025 showed ELI-002 7P induced mutant KRAS (mKRAS)-specific T cell responses in 99% (89/90) of evaluable patients with an 86% antigen response rate.
• 86.8% (66/76) of evaluable patients induced cytotoxic mKRAS-specific T cell responses, with 75% inducing CD8+ T cells and 75% inducing CD4+ T cells.
• An investigator-initiated Phase 1 neoadjuvant trial of ELI-002 7P in resectable and borderline resectable PDAC, led by Memorial Sloan Kettering Cancer Center and funded by the Lustgarten Foundation, is anticipated to begin in 1H 2026.
• The Independent Data Monitoring Committee (IDMC) provided a positive recommendation in August 2025 to continue the ELI-002 7P randomized Phase 2 study without modifications and confirmed its favorable safety profile.

Sentiment

Score: 7

Explanation: The filing presents several positive clinical updates, including fewer disease progressions and strong T-cell responses, which are encouraging for the ELI-002 7P program. The successful capital raise extends the cash runway beyond a critical data readout. While there is a delay in the primary DFS analysis, it is attributed to positive clinical observations (fewer events), which is a favorable reason. The financial results show improved net loss.

Positives

• Fewer disease progressions and deaths than projected in the Phase 2 AMPLIFY-7P study, potentially indicating a favorable impact on disease-free survival (DFS).
• Successful capital raise of approximately $11.1 million through an at-the-market program, extending the cash runway through Q2 2026, which covers the anticipated Phase 2 DFS analysis.
• Significant reduction in net loss from $18.8 million in Q3 2024 to $10.1 million in Q3 2025.
• Improved net loss per share from $1.39 in Q3 2024 to $0.60 in Q3 2025.
• Strong T cell responses observed in Phase 2 AMPLIFY-7P data, with 99% of evaluable patients showing mKRAS-specific T cell responses and an 86% antigen response rate.
• Positive recommendation from the Independent Data Monitoring Committee (IDMC) to continue the Phase 2 study without modifications and confirmation of a favorable safety profile, suggesting preliminary efficacy signals.
• Planned investigator-initiated Phase 1 neoadjuvant trial for ELI-002 7P, indicating further development and external validation of the therapy.

Negatives

• The event-driven primary DFS analysis for the Phase 2 AMPLIFY-7P trial is now anticipated in 1H 2026, representing a delay from original projections, although attributed to positive clinical observations.
• The company continues to report a net loss of $10.1 million for Q3 2025, reflecting its clinical-stage status and ongoing R&D expenses.

Risks

• The sufficiency of existing cash and cash equivalents to support operations and the ability to obtain necessary funding to advance product candidates.
• The company's ability to continue as a going concern.
• The timing and outcome of planned clinical trials, including the event-driven primary DFS endpoint analysis from the Phase 2 AMPLIFY-7P trial.
• The potential efficacy of Elicio's product candidates, including ELI-002 7P, to meaningfully improve outcomes for mKRAS PDAC patients.
• The potential outcome of the End of Phase 2 meeting with the FDA to finalize the Phase 3 trial design.
• The ability to successfully expand ELI-002 to other indications, such as mKRAS positive lung cancer and other mKRAS positive cancers.
• Actual results may differ materially from forward-looking statements due to various factors, including those discussed in previous SEC filings.

Future Outlook

The company anticipates the event-driven primary DFS endpoint analysis for the Phase 2 AMPLIFY-7P trial in the first half of 2026. Following this, Elicio plans to request an End of Phase 2 meeting with the FDA to finalize the Phase 3 trial design for ELI-002 7P. The current cash position is expected to fund operations through Q2 2026, beyond this critical catalyst. Elicio also plans to expand ELI-002 to other indications like mKRAS positive lung cancer and other mKRAS positive cancers. An investigator-initiated Phase 1 neoadjuvant trial for ELI-002 7P is expected to begin in 1H 2026.

Management Comments

• "We are encouraged to see fewer disease progressions and deaths in the Phase 2 AMPLIFY-7P study than originally projected in our statistical modeling. This may reflect a favorable impact on DFS."
• "Because the DFS analysis is event-driven and triggered by a predefined number of events, we are updating our guidance for the timing of the event-driven primary DFS endpoint analysis to the first half of 2026."
• "Importantly, we believe our current cash position will allow us to reach this critical catalyst and beyond as we continue advancing ELI-002 7P toward its potential to meaningfully improve outcomes for patients with KRAS-mutant pancreatic cancer."

Industry Context

Elicio Therapeutics operates in the highly competitive clinical-stage biotechnology sector, specifically focusing on novel immunotherapies for high-prevalence cancers driven by mutations like KRAS. The company aims to develop "off-the-shelf" immunotherapies, which offer potential benefits like lower cost, rapid manufacturing, and quicker patient access compared to personalized approaches. This strategy positions Elicio to address a broad patient population, particularly in mKRAS-positive pancreatic and colorectal cancers, and potentially lung cancer. The focus on lymph node-targeted delivery via its Amphiphile (AMP) platform is a differentiating factor in the immunotherapy landscape, aiming to enhance immune cell education and activation.

Comparison to Industry Standards

• Elicio intends to build on recent clinical successes in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies.
• Off-the-shelf immunotherapy approaches, such as ELI-002, have the potential benefits of low cost, rapid commercial scale manufacturing, and rapid availability of drug to patients, especially in neo-adjuvant settings and for prophylaxis in high-risk patients, which contrasts with personalized immunotherapy approaches.
• Elicio believes its AMP lymph node-targeted approach will produce superior clinical benefits compared to immunotherapies that do not engage the lymph nodes, based on preclinical studies.
• The updated AMPLIFY-201 Phase 1 data for PDAC and CRC included a 16.3-month median recurrence-free survival and 28.9-month median overall survival for the full study population, which provides a benchmark for future efficacy comparisons within the mKRAS-positive cancer treatment landscape.

Stakeholder Impact

• Shareholders: Potential positive impact due to encouraging clinical data, extended cash runway, and reduced net loss, but also a delay in key data readout.
• Patients (with mKRAS-mutant PDAC): Potential positive impact from a promising new therapy (ELI-002 7P) showing favorable preliminary signals and safety.
• Employees: Continued operations and progress in clinical development.
• Creditors: Improved financial stability with extended cash runway.

Next Steps

• Event-driven primary DFS endpoint analysis for Phase 2 AMPLIFY-7P trial in 1H 2026.
• Request an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to finalize the Phase 3 trial design for ELI-002 7P.
• Initiation of investigator-initiated Phase 1 neoadjuvant trial of ELI-002 7P in 1H 2026.
• Potential future expansion of ELI-002 to other indications, including mKRAS positive lung cancer and other mKRAS positive cancers.

Key Dates

Recommendation

The filing contains significant positive clinical data, including fewer disease progressions and strong T-cell responses, which are encouraging for the ELI-002 7P program. The successful capital raise extends the cash runway beyond a critical data readout, mitigating immediate financing concerns. However, the delay in the primary DFS analysis, while for a positive reason, still pushes back a key catalyst. The company remains in a clinical-stage, pre-revenue phase with ongoing losses. Given the mix of promising clinical progress and extended runway against the inherent risks of drug development and the delay in definitive efficacy data, a "hold" recommendation is appropriate. Investors should await the full DFS analysis in 1H 2026 for a clearer picture of the drug's potential.

Keywords

Elicio Therapeutics, ELTX, ELI-002 7P, AMPLIFY-7P, pancreatic cancer, PDAC, mKRAS, KRAS-mutant, immunotherapy, oncology, clinical trial, Phase 2, DFS, disease-free survival, biotechnology, financial results, cash runway, capital raise, ATM program, T cell response, FDA, IDMC